Sodium tetradecyl sulfate

Overview

An anionic surface-active agent used for its wetting properties in industry and used in medicine as an irritant and sclerosing agent for hemorrhoids and varicose veins.

Indication

For the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves.

Associated Conditions

Uncomplicated competent valves, simple dilation varicose veins of legs

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Balloon-occluded Retrograde Transvenous Obliteration for Gastric Variceal Rebleeding	2023/10/30	NCT06106971	Phase 3	Recruiting	Kaohsiung Veterans General Hospital.
Treatment of Epidermoid Cysts	2022/10/28	NCT05597995	Phase 2	Not yet recruiting	Goldman, Butterwick, Fitzpatrick and Groff
is Ultrasound-guided Foam Sclerotherapy a Cost-effective Alternate for Treatment of Varicose Veins?	2020/12/07	NCT04655417	Early Phase 1	UNKNOWN	Combined Military Hospital, Pakistan
Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study	2018/07/11	NCT03582800	Phase 2	Recruiting	University Hospital, Limoges
Perforator Vein Injection for Symptomatic Venous Disease	2017/12/06	NCT03363633	Not Applicable	Terminated	Ellen Dillavou
Laser Ablation Versus Mechanochemical Ablation Trial	2015/12/11	NCT02627846	Phase 4	Completed	Hull University Teaching Hospitals NHS Trust

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Sodium Tetradecyl Sulfate	Hikma Pharmaceuticals USA Inc. (dba Leucadia Pharmaceuticals)	24201-201	INTRAVENOUS	30 mg in 1 mL	1/10/2023

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
FIBRO-VEIN SOLUTION FOR INJECTION 0.5% W/V	N/A	SINO-ASIA PHARMACEUTICAL SUPPLIES LIMITED	N/A	N/A	11/11/2013
FIBRO-VEIN SOLUTION FOR INJECTION 3% W/V	N/A	SINO-ASIA PHARMACEUTICAL SUPPLIES LIMITED	N/A	N/A	11/11/2013
FIBRO-VEIN SOLUTION FOR INJECTION 1% W/V	N/A	SINO-ASIA PHARMACEUTICAL SUPPLIES LIMITED	N/A	N/A	11/11/2013

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
FIBROVEIN 0.5% sodium tetradecyl sulfate 10mg/2mL injection ampoule	73361	Intermed Medical Pty Ltd	Medicine	A	9/4/2000
FIBROVEIN 3% sodium tetradecyl sulfate 30mg/1mL multidose injection vial	29772	Intermed Medical Pty Ltd	Medicine	A	10/25/1991
FIBROVEIN 1.0% sodium tetradecyl sulfate 20mg/2ml injection ampoule	73362	Intermed Medical Pty Ltd	Medicine	A	9/4/2000
FIBROVEIN 3% sodium tetradecyl sulfate 60mg/2mL injection ampoule	29638	Intermed Medical Pty Ltd	Medicine	A	10/25/1991

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
TROMBOJECT 1%	omega laboratories limited	00511234	Solution - Intravenous	10 MG / ML	12/31/1987
TROMBOJECT 3%	omega laboratories limited	00511226	Solution - Intravenous	30 MG / ML	12/31/1987
TROMBOVAR INJ 3%	therapex division de e-z-em canada inc	00363340	Solution - Intravenous	3 %	12/31/1976
SOTRADECOL	Mylan Pharmaceuticals ULC	02347784	Solution - Intravenous	3 %	N/A
SOTRADECOL	Mylan Pharmaceuticals ULC	02347776	Solution - Intravenous	1 %	N/A
TROMBOVAR INJ 1%	therapex division de e-z-em canada inc	00363332	Solution - Intravenous	1 %	12/31/1976

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

Adcendo's ADCE-D01 Receives FDA Clearance for Phase I/II Soft Tissue Sarcoma Trial

a year ago

• Adcendo's ADCE-D01, a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, has received FDA clearance for a Phase I/II trial in metastatic and/or unresectable soft tissue sarcoma (STS). • The ADCElerate-01 trial will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ADCE-D01 as a monotherapy in STS patients. • uPARAP, the target of ADCE-D01, is highly overexpressed in mesenchymal cancers like STS, making it an attractive target for ADC development. • The trial will recruit patients in the US and Europe, marking a significant step in developing new treatment options for STS with limited alternatives.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access